Pharmaceutical intermediates
Quizartinib Intermediates
3 pharmaceutical intermediates for Quizartinib. Indication: Acute myeloid leukemia; Myeloid leukemia.
About Quizartinib
- Originator
- Ambit Biosciences Co
- Indication
- Acute myeloid leukemia; Myeloid leukemia
- Approved Date
- 07/20/2023
- NCE Patent
- 07/20/2028
- DS/DP
- 03/16/2027
Available intermediates
3 intermediates currently listed for Quizartinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester | 81479-48-3 | / | / |
| 4-(2-Chloroethyl)morpholine hydrochloride | 3647-69-6 | / | / |
| 3-Amino-5-tert-butylisoxazole | 55809-36-4 | / | / |
Building toward Quizartinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →